Market Runner: Is Buying Genocea Biosciences Inc Here a Winning Strategy?

Market Runner: Is Buying Genocea Biosciences Inc Here a Winning Strategy?

The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! About 188,418 shares traded hands. Genocea Biosciences Inc (NASDAQ:GNCA) has declined 51.18% since April 5, 2016 and is downtrending. It has underperformed by 53.13% the S&P500.
The move comes after 6 months positive chart setup for the $100.45M company. It was reported on Nov, 7 by Barchart.com. We have $7.56 PT which if reached, will make NASDAQ:GNCA worth $116.52M more.

Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage

Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by Piper Jaffray on Thursday, August 6. The rating was maintained by Needham on Thursday, September 29 with “Buy”. The firm earned “Buy” rating on Tuesday, August 11 by Needham. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Outperform” rating given on Monday, October 19 by FBR Capital. Needham maintained it with “Buy” rating and $15 target price in Tuesday, October 20 report. The firm earned “Overweight” rating on Thursday, September 29 by PiperJaffray. UBS initiated the shares of GNCA in a report on Thursday, December 17 with “Buy” rating.

According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: Fool.com which released: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” on April 01, 2016, also 247Wallst.com with their article: “Genocea Biosciences Rises on Positive Herpes Trial Results” published on October 29, 2016, Fool.com published: “Why Genocea Biosciences Inc Stock Dropped Today” on July 30, 2015. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) were released by: Wsj.com and their article: “Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals” published on October 19, 2015 as well as 247Wallst.com‘s news article titled: “Genocea Biosciences Posts Positive Herpes Trial Results” with publication date: September 29, 2016.

GNCA Company Profile

Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment